canakinumab
novartis
['canakinumab']
germany based 74 pt #fmf prospective non-interventional, multicenter observational study on canakinumab - reliance registry
63% in remission in 2 yrs
serious adverse drug reactions - 1.56 per 100 patient years #acr22 abst#0138
Rheumatologist @HSpecialSurgery @WeillCornell ClinicalResearch | Big Data | Outcomes | Epidemiology | Disparities | Table tennis player | Tweets are my own.